Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin’s lymphoma

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Nishimura H, Nose M, Hiai H, Minato N, Honjo T . Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141–151.

    Article  CAS  Google Scholar 

  2. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N . Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci 2002; 99: 12293–12297.

    Article  CAS  Google Scholar 

  3. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537–1544.

    Article  CAS  Google Scholar 

  4. Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–264.

    Article  CAS  Google Scholar 

  5. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116: 3268–3277.

    Article  CAS  Google Scholar 

  6. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A . The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010; 221: 248–263.

    Article  CAS  Google Scholar 

  7. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013; 19: 3462–3473.

    Article  CAS  Google Scholar 

  8. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al. PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311–319.

    Article  Google Scholar 

  9. Moskowitz CH, Ribrag V, Michot J-M, Martinelli G, Zinzani PL, Gutierrez M et al. PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013). 2014. Abstract 290.

  10. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen Y-B et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international Phase ii trial. J Clin Oncol 2013; 31: 4199–4206.

    Article  CAS  Google Scholar 

  11. Villasboas JC, Ansell SM, Witzig TE . Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective. Oncotarget (e-pub ahead of print 3 February 2016; doi:10.18632/oncotarget.7177).

  12. Mori S, Ahmed W, Patel RD, Dohrer AL . Steroid refractory acute liver GvHD in a Hodgkin's patient after allogeneic stem transplant cell transplantation following treatment with anti PD-1 antibody, nivolumab, for relapsed disease. Biol Blood Marrow Transplant 22: S392–S393.

    Article  Google Scholar 

  13. Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M et al. Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 2015; 51: 443–445.

    Article  Google Scholar 

  14. Fife BT, Bluestone JA . Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008; 224: 166–182.

    Article  CAS  Google Scholar 

  15. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism. J Immunol 2003; 171: 1272–1277.

    Article  CAS  Google Scholar 

  16. Keir ME, Butte MJ, Freeman GJ, Sharpe AH . PD-1 and Its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677–704.

    Article  CAS  Google Scholar 

  17. Saha A, Aoyama K, Taylor PA, Koehn BH, Veenstra RG, Panoskaltsis-Mortari A et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood 2013; 122: 3062–3073.

    Article  CAS  Google Scholar 

  18. Deng R, Cassady K, Li X, Yao S, Zhang M, Racine J et al. B7H1/CD80 interaction augments PD-1–dependent T Cell apoptosis and ameliorates graft-versus-host disease. J Immunol 2015; 194: 560–574.

    Article  CAS  Google Scholar 

  19. Amarnath S, Mangus CW, Wang JCM, Wei F, He A, Kapoor V et al. The PDL1-PD1 axis converts human Th1 cells into regulatory T Cells. Sci Transl Med 2011; 3: 111ra120.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A K Singh.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, A., Porrata, L., Aljitawi, O. et al. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin’s lymphoma. Bone Marrow Transplant 51, 1268–1270 (2016). https://doi.org/10.1038/bmt.2016.111

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.111

This article is cited by

Search

Quick links